Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.38 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11934845 | 1.00 | PRKCQ (0.42) | PRKCQKMT2ACRHR1CYP3A4TSHR | |
| SCHEMBL11934757 | 0.84 | PRKCQ (0.43) | PRKCQKMT2ACRHR1CYP3A4POLB | |
| SCHEMBL13438643 | 0.84 | PRKCQ (0.43) | PRKCQKMT2ACRHR1CYP3A4POLB | |
| SCHEMBL13438917 | 0.81 | CRHR1 (0.47) | PRKCQKMT2ACRHR1ALDH1A1VCP | |
| SCHEMBL11935235 | 0.81 | CRHR1 (0.47) | PRKCQKMT2ACRHR1ALDH1A1VCP | |
| SCHEMBL13439105 | 0.81 | POLB (0.54) | PRKCQCRHR1POLBALDH1A1VCP | |
| SCHEMBL13462869 | 0.81 | PRKCQ (0.42) | PRKCQCRHR1POLB | |
| SCHEMBL13439216 | 0.81 | PRKCQ (0.42) | PRKCQCRHR1POLB | |
| SCHEMBL11935118 | 0.81 | POLB (0.54) | PRKCQCRHR1POLBALDH1A1VCP | |
| SCHEMBL1846502 | 0.80 | CARM1 (0.50) | PRKCQCRHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | NPY5R, NPY1R, NPY2R | PRKCQ 3402/4885KMT2A 2031/4885CRHR1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.